Welcome to our dedicated page for Syra Health news (Ticker: SYRA), a resource for investors and traders seeking the latest updates and insights on Syra Health stock.
Syra Health Corp. (SYRA) is a leading healthcare technology company focused on improving population health outcomes through innovative behavioral health solutions and workforce development programs. This page provides official updates and press releases directly from Syra Health, offering stakeholders timely insights into strategic initiatives.
Investors and healthcare professionals will find comprehensive coverage of SYRA's latest developments, including new contract awards, digital health product launches, and partnerships with government agencies. The curated news collection serves as a reliable resource for tracking the company's progress in mental health innovation and preventative care technologies.
All content is sourced from verified corporate communications, ensuring accuracy across updates about population health management systems, healthcare training advancements, and AI-driven behavioral health tools. Regular visitors can monitor SYRA's growing influence in addressing critical challenges like workforce shortages and health equity gaps.
Bookmark this page for streamlined access to Syra Health's evolving role in shaping healthcare delivery through science-driven solutions and measurable community impact.
Syra Health (NASDAQ: SYRA) has secured two significant contracts: a new healthcare workforce contract with the Washington D.C. government valued at up to $1 million, and a $1.2 million extension to an existing contract with Indiana's NeuroDiagnostic Institute, bringing its total value to $18.7 million.
The D.C. contract, awarded on behalf of the Office of the State Superintendent of Education, involves deploying registered nurses, licensed practical nurses, and certified nursing assistants to provide healthcare services to students. This one-year agreement includes extension options and requires developing individualized service plans for students.
The expanded Indiana contract continues Syra Health's support in providing healthcare professionals to evaluate and treat patients with complex neuropsychiatric illnesses at the NeuroDiagnostic Institute. This marks Syra Health's fourth contract with the D.C. government, building on their partnership with the NeuroDiagnostic Institute that began in 2021.
Syra Health (NASDAQ: SYRA) has launched Syrenity, an AI-powered mental health app now available for adults 18+ on App Store and Google Play. The app combines cognitive behavioral therapy, mindfulness-based stress reduction, and neuroscience research to address stress, anxiety, and depression. Features include a 24/7 AI companion named Echo, personalized assessments, and real-time progress tracking.
Developed by clinical psychologists, neuroscientists, and data scientists, Syrenity offers HIPAA-compliant mental health support with advanced encryption. The app enters a global mental health app market projected to grow from $6 billion in 2023 to over $30 billion by 2033. Beyond consumer use, Syrenity is available as a B2B solution for healthcare providers, payers, and academic institutions.
Syra Health (NASDAQ: SYRA) announced its participation in the Noble Financial Capital Markets 20th Annual Equity Conference (NobleCon20) scheduled for December 3-4 in Boca Raton, Florida. CEO Dr. Deepika Vuppalanchi will present on December 3 at 2:00 p.m. ET, showcasing the company's healthcare solutions focused on mental health crisis, chronic conditions, and child welfare challenges.
The presentation will be followed by a fireside chat and one-on-one investor meetings. CFO Priya Prasad will also attend the event. The company reports strong revenue growth and expanding market presence, positioning itself to meet increasing demand for innovative healthcare solutions.
Syra Health (NASDAQ: SYRA) reported Q3 2024 financial results with net revenue of $2.3 million, representing 42% growth year-over-year. The company's gross profit margin was 30%, and net loss narrowed to $417,535 ($0.06 per share), showing a 69% reduction compared to Q2 2024. Population Health revenues grew 36% while Healthcare Workforce services increased 54%. The company implemented significant cost-saving measures, reducing operating expenses by 37% quarter-over-quarter. With $2.7 million cash balance and no long-term debt, Syra Health aims to achieve profitability in 2025.
Syra Health Corp. (NASDAQ: SYRA), a healthcare technology company, has announced it will report its financial results for the third quarter of 2024 on Tuesday, October 29, 2024, before the market opens. The company has scheduled a conference call for the same day at 9:00 a.m. ET to review the results.
Interested parties can access the conference call via Internet webcast, available in the Investors section of the company's website. Investors who wish to submit questions for the call can email them to christined@syrahealth.com. A webcast replay will also be available in the Investors section of Syra Health's website after the call.
Syra Health Corp. (NASDAQ: SYRA) has announced it will report its financial results for the third quarter of 2024 on Tuesday, October 29, 2024, before the market opens. The company has scheduled a conference call at 9:00 a.m. ET on the same day to review the results.
Interested parties can access the conference call via an Internet webcast available in the Investors section of the company's website. The correct URL for the webcast is https://syrahealth.com/ir/presentations/q3-2024-earnings-call.
Investors who wish to submit questions to be addressed during the call should email them to christined@syrahealth.com. A webcast replay will also be available in the Investors section of the company's website after the call.
Syra Health Corp. (NASDAQ: SYRA) has been awarded three new healthcare workforce contracts across multiple states. In Florida, Syra Health will supply psychologists and school counselors to the St. John's County School District. In Kansas, the company will provide temporary nursing personnel, including registered nurses, licensed practical nurses, certified nurse aides, certified medication aides, and nurse practitioners. In Delaware, Syra Health will provide licensed dieticians for the Delaware Veterans Home.
These contracts showcase Syra Health's expertise in delivering tailored healthcare solutions and addressing workforce shortages. The value of these contracts is currently under negotiation and will depend on the number of positions filled and the duration of services. Syra Health's Healthcare Workforce business unit aims to improve patient care and health outcomes by filling gaps left by workforce shortages.
Syra Health Corp. (NASDAQ: SYRA) is celebrating its first anniversary as a publicly traded company, highlighting significant achievements and growth. The healthcare technology company has increased quarterly revenue by 47% in Q1 2024 and 101% in Q2 2024 compared to the previous year. Syra Health has expanded its presence to 24 states and is a subcontractor on two federal contracts with a combined ceiling value of $118 Billion.
The company has secured multiple contract wins across all business units, including recent Healthcare Workforce contracts in Delaware, Florida, and Kansas. Syra Health successfully raised $2.1 Million in capital for the development of Syrenity, their mental health app, and other initiatives. The company is focusing on high-margin business units, implementing cost reduction strategies, and working towards profitability while continuing to innovate in healthcare solutions.
Syra Health Corp. (NASDAQ: SYRA) has announced the closing of its previously announced public offering, raising approximately $2.1 million before deducting fees and expenses. The offering included 3,203,125 shares of Class A common stock, along with Series A and Series B warrants to purchase up to 3,203,125 shares each, at a combined price of $0.64 per share and accompanying warrants.
The warrants have an exercise price of $0.64 per share, with Series A expiring in 18 months and Series B in 5 years. If fully exercised, the warrants could potentially bring in an additional $4.1 million. Syra Health plans to use the net proceeds for application development, sales and marketing, research and development, and general corporate purposes.
Syra Health Corp. (NASDAQ: SYRA) has announced the pricing of a $2.1 million public offering. The offering includes 3,203,125 shares of Class A common stock, along with Series A and Series B warrants to purchase additional shares. Priced at $0.64 per share and accompanying warrants, the offering is expected to close around September 13, 2024. If all warrants are exercised, it could generate an additional $4.1 million. Rodman & Renshaw is the exclusive placement agent. Syra Health plans to use the proceeds for marketing, sales, application development, research, and general corporate purposes. The offering is made pursuant to an effective SEC registration statement.
FAQ
What is the current stock price of Syra Health (SYRA)?
What is the market cap of Syra Health (SYRA)?
